

Bulletin #1101

March 27, 2023

NB Drug Plans Formulary Update

This update to the New Brunswick Drug Plans Formulary is effective March 27, 2023.

Included in this bulletin:

- Special Authorization Benefit Additions
- Drugs Reviewed and Not listed

If you have any questions, please contact our office at 1-800-332-3691.

Special Authorization Benefit Additions

Generic name (Brand name)	Strength	DIN	MFR	Plans	Cost Base
Tucatinib (Tukysa)	50 mg tablet 150 mg tablet	02499827 02499835	SGC	(SA)	MLP

In combination with trastuzumab and capecitabine for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab, pertuzumab and a HER2-targeted antibody-drug conjugate (e.g., Kadcyca, Enhertu), where at least one was given in the advanced or metastatic setting.

Renewal Criteria:

- Written confirmation that the patient has responded to treatment and there is no evidence of disease progression.

Clinical Notes:

1. Patients must have a good performance status.
2. Treatment should be discontinued upon disease progression, unacceptable toxicity, or if both trastuzumab and capecitabine are discontinued.

Claim Note:

- Approval period: 6 months

Drugs Reviewed and Not Listed

Requests for special authorization of the following products will not be considered.

Generic name (Brand name)	Strength	DIN	MFR	Indication
Alpelisib (Piqray)	150 mg tablet	02497069		In combination with fulvestrant, for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen with a CDK4/6 inhibitor.
	200 mg tablet	02497077	NVR	
Alpelisib (Piqray) kit	50 mg, 200 mg tablet	02497085		